Insights of SEDRIC, the Surveillance and Epidemiology of Drug-Resistant Infections Consortium [version 1; peer review: 2 approved]

Insights of SEDRIC, the Surveillance and Epidemiology of Drug-Resistant Infections Consortium [version 1; peer review: 2 approved]

The increasing threat from infection with drug-resistant pathogens is among the most serious public health challenges of our time. Formed by Wellcome in 2018, the Surveillance and Epidemiology of Drug-Resistant Infections Consortium (SEDRIC) is an international think tank whose aim is to inform poli...

Full description

Saved in:
Bibliographic Details
Main Authors: Paul Turner, Nicholas Feasey, Kate S Baker, Rifat Atun, H. Rogier van Doorn, Francesca Chiari, Andrew Jermy, Timothy Jinks, Matt King, Souha S Kanj, Mirfin Mpundu, Janet Midega, Stuart Reid, Jamie Nunn, Kamini Walia, Dawn Sievert, Sharon J Peacock, Elizabeth Ashley, Direk Limmathurotsakul, Raheelah Ahmad, Iruka N. Okeke, Jyoti Joshi, Alison Holmes
Format: Article
Language:English
Published: Wellcome 2025-01-01
Series:Wellcome Open Research
Subjects:
Antimicrobial resistance
surveillance
eng
Online Access:https://wellcomeopenresearch.org/articles/10-5/v1
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The increasing threat from infection with drug-resistant pathogens is among the most serious public health challenges of our time. Formed by Wellcome in 2018, the Surveillance and Epidemiology of Drug-Resistant Infections Consortium (SEDRIC) is an international think tank whose aim is to inform policy and change the way countries track, share, and analyse data relating to drug-resistant infections, by defining knowledge gaps and identifying barriers to the delivery of global surveillance. SEDRIC delivers its aims through discussions and analyses by world-leading scientists that result in recommendations and advocacy to Wellcome and others. As a result, SEDRIC has made key contributions in furthering global and national actions. Here, we look back at the work of the consortium between 2018-2024, highlighting notable successes. We provide specific examples where technical analyses and recommendations have helped to inform policy and funding priorities that will have real-world impact on the surveillance and epidemiology of infections with drug-resistant pathogens.
ISSN:2398-502X

Similar Items